In Re Yasmin & Yaz (Drospirenone) Marketing, Sales Practices & Products Liability Litigation , 655 F. Supp. 2d 1343 ( 2009 )

655 F. Supp. 2d 1343 (2009)

In re YASMIN and YAZ (DROSPIRENONE) MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION.

MDL No. 2100.

United States Judicial Panel on Multidistrict Litigation.

October 1, 2009.

Before ROBERT L. MILLER, JR. Acting Chairman, JOHN G. HEYBURN II, Chairman^[*], KATHRYN H. VRATIL, DAVID R. HANSEN, W. ROYAL FURGESON, JR. and FRANK C. DAMRELL, JR., Judges of the Panel.

TRANSFER ORDER

ROBERT L. MILLER, JR., Acting Chairman.

Before the entire Panel^[*]: Plaintiffs in 24 actions and three related actions move, pursuant to 28 U.S.C. § 1407, for coordinated or consolidated pretrial proceedings of the 32 actions listed on Schedule A in the Northern District of Ohio. The plaintiffs' motion encompasses fourteen actions in the Northern District of Ohio, six actions in the Eastern District of Pennsylvania, five actions in the Northern District of California, two actions in the Southern District of Ohio, and one action each in the Eastern District of California, Northern District of Georgia, Eastern District of New York, District of Puerto Rico and the Eastern District of Wisconsin.^[1]

Plaintiffs in the Eastern District of California action (Brownfield) oppose the motion as it relates to their action and argue for exclusion of their action from any centralized proceedings. Although moving plaintiffs included the Brownfield action on their motion, they agree to the exclusion of this action from any centralized proceedings. Defendants Bayer Corp., Bayer HealthCare Pharmaceuticals Inc., on its own behalf and as successor by merger to Bayer Pharmaceuticals Corp.,^[2] and Bayer HealthCare LLC (collectively Bayer) support centralization of all actions, including the Brownfield action, in the Northern District of Ohio.

All other responding plaintiffs support centralization but disagree upon the appropriate transferee district. These responding plaintiffs variously support centralization in the District of Colorado, Southern District of Illinois, Eastern District of New York, Northern District of Ohio, Eastern District of Pennsylvania, or the Eastern District of Texas.

On the basis of the papers filed and hearing session held, we find that these 32 actions involve common questions of fact, and that centralization under Section 1407 in the Southern District of Illinois will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. All actions share factual questions relating to at least one of the drospirenone-containing oral contraceptives Yaz and Yasmin, which are manufactured by Bayer. Plaintiffs in the products liability actions challenge the safety of those oral contraceptives and bring claims for personal injuries or wrongful death stemming from use of the drugs. Plaintiffs in the Brownfield action bring claims arising from the advertising of Yaz on behalf of a putative nationwide class of purchasers of Yaz. Centralization under Section 1407 will eliminate duplicative discovery, prevent inconsistent pretrial rulings, and conserve the resources of the parties, their counsel and the judiciary.

Plaintiffs in the Brownfield action argue that their action does not share questions of fact with the other actions and accordingly to exclude it from MDL No. 2100. For the following reasons, we respectfully disagree with this argument. Plaintiffs in all actions seek to hold Bayer responsible for harm allegedly arising out of the purchase and use of the oral contraceptives Yaz and/or Yasmin. Like the plaintiffs in the Brownfield action, plaintiffs in several products liability actions also allege economic injury and violation of consumer protection statutes. Similarly, complaints in the products liability actions reference the television advertisements at issue in the Brownfield action. Moreover, the Panel has frequently combined actions involving claims relating to sales and marketing of medications with actions involving personal injury claims from use of the same pharmaceutical products.^[3] Transfer under Section 1407 will offer the benefit of placing all actions in this docket before a single judge who can structure pretrial proceedings to consider all parties' legitimate discovery needs while ensuring that common parties and witnesses are not subjected to discovery demands that duplicate activity that will occur or has already occurred in other actions.

Distinctions among the actions may lead to certain actions or claims therein becoming ready for remand in advance of other claims or actions, after further refinement of the issues and close scrutiny by the transferee judge. But we are unwilling, on the basis of the record before us, to make a determination that any claims warrant exclusion from Section 1407 proceedings at the outset. Whenever the transferee judge deems remand of any claims or actions appropriate, procedures are available to accomplish this with a minimum of delay. See Rule 7.6, R.P.J.P.M.L., 199 F.R.D. at 436-38.

We are persuaded that the Southern District of Illinois is an appropriate forum for this docket. Centralization in this district, where related actions are already pending, permits the Panel to effect the Section 1407 assignment to an experienced transferee judge who is not currently presiding over another multidistrict litigation docket and who has a caseload favorable to accepting this assignment. This district also provides a geographically central forum for this nationwide litigation in which actions are pending in various districts across the country.

IT IS THEREFORE ORDERED that, pursuant to 28 U.S.C. § 1407, the actions listed on Schedule A are transferred to the Southern District of Illinois and, with the consent of that court, assigned to the Honorable David R. Herndon for coordinated or consolidated pretrial proceedings in that district.

SCHEDULE A

MDL No. 2100—IN RE: YASMIN and YAZ (DROSPIRENONE) MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION.

Eastern District of California

Nichole Brownfield, et al. v. Bayer Corp., et al., C.A. No. 2:09-444

Northern District of California

Bridget Renee Tanner, et al. v. Bayer Corp., et al., C.A. No. 4:09-1558

Stephanie D. Ivey v. Bayer Corp., et al., C.A. No. 4:09-1904

Dawn Voss v. Bayer Corp., et al., C.A. No. 4:09-1905

Tamera Jirbi v. Bayer Corp., et al., C.A. No. 4:09-2416

Bieanca White v. Bayer Corp., et al., C.A. No. 4:09-2417

Northern District of Georgia

James Parivechio, III, et al. v. Bayer Corp., et al., C.A. No. 3:09-81

Eastern District of New York

Debra Casali v. Bayer Corp., et al., C.A. No. 2:09-686

Northern District of Ohio

Marlene Meadows v. Bayer Corp., et al., C.A. No. 1:09-1574

Anne Marie Eakins, et al. v. Bayer Corp., et al., C.A. No. 1:09-1579

Lauren L. Murphy v. Bayer Corp., et al., C.A. No. 1:09-1582

Marie Claire Keultjes v. Bayer Corp., et al., C.A. No. 1:09-1659

Candace L. Fries, etc. v. Bayer Corp., et al., C.A. No. 3:09-1085

Angela Beck, et al. v. Bayer Corp., et al., C.A. No. 3:09-1207

Bridget Shafer, et al. v. Bayer Corp., et al., C.A. No. 3:09-1315

Gail Brinker, et al. v. Bayer Corp., et al., C.A. No. 3:09-1682

Carla Leigh Brazzel v. Bayer Corp., et al., C.A. No. 3:09-1684

Kathy Johns, et al. v. Bayer Corp., et al., C.A. No. 3:09-1685

Brenda Ellyson v. Bayer Corp., et al., C.A. No. 3:09-1687

Saretta Main, et al. v. Bayer Corp., et al., C.A. No. 3:09-1688

Patti Bradish, et al. v. Bayer Corp., et al., C.A. No. 3:09-1689

Lauren Cathis v. Bayer Corp., et al., C.A. No. 3:09-1690

Southern District of Ohio

Heather Riley v. Bayer Corp., et al., C.A. No. 1:09-387

Valerie Kozak, et al. v. Bayer Corp., et al., C.A. No. 3:09-281

Eastern District of Pennsylvania

Alyssa S. Britten v. Bayer Pharmaceuticals Corp., et al., C.A. No. 2:09-2086

Adine Gauthreaux, et al. v. Bayer Corp., et al., C.A. No. 2:09-2238

LaKollier R. Cleveland v. Bayer Corp., et al., C.A. No. 2:09-2740

Danielle C. Hayat, et al. v. Bayer Corp., et al., C.A. No. 2:09-2753

Deborah Kay Lane-Christian, et al. v. Bayer Corp., et al., C.A. No. 2:09-3114

Silvia F. Galvan, et al. v. Bayer Corp., et al., C.A. No. 5:09-2739

District of Puerto Rico

Maria Isabel Pujals-Torregrosa v. Berlex, Inc., et al., C.A. No. 3:07-1271

Eastern District of Wisconsin

Marie Becker v. Bayer Corp., et al., C.A. No. 1:09-663

NOTES

[*] Judge Heyburn took no part in the decision of this matter.

[1] The parties have notified the Panel of 60 related actions pending in various federal districts. These actions and any other related actions are potential tag-along actions. See Rules 7.4 and 7.5, R.P.J.P.M.L., 199 F.R.D. 425, 435-36 (2001).

[2] Bayer HealthCare Pharmaceuticals Inc. was formerly known as Berlex, Inc., which was formerly known as Berlex Laboratories, Inc.

[3] See, e.g., In re Vytorin/Zetia Marketing, Sales Practices and Products Liability Litigation, 543 F. Supp. 2d 1378 (J.P.M.L.2008); In re Avandia Marketing, Sales Practices and Products Liability Litigation., 528 F. Supp. 2d 1339 (J.P.M.L.2007).